Dr. Juan Espinosa Pereiro

EDUCATION
2007-2013: Degree with Extraordinary Award in Medicine. Universidade de Santiago de Compostela.
PhD candidate: “Mycobacterium tuberculosis resistance to and optimization of first line drugs.” October 2019 to present: Universitat Autónoma de Barcelona, Barcelona, Cataluña, Spain. Director: Adrián Sánchez-Montalvá.
Residence May 2014 -May 2019: Internal Medicine. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Cataluña, Spain.
Subspecialization May 2017 to May 2019: Infectious Diseases. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Cataluña, Spain.
Internships November-December 2018: Tropical Diseases Oxford University Clinical Research Unit Vietnam, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
October-December 2019 and June-July 2022: Tuberculosis Instituto de Enfermedades Respiratorias y del Ambiente (INERAM), Asunción, Paraguay. Programa Nacional de Control de la Tuberculosis (PNCT), Asunción Paraguay.

PROFESSIONAL EXPERIENCE
Licensed Physician number 50420, in Barcelona, 2014.
May 2019 to present: Emergency Department, attending physician.
May 2019 to present: Global Health and Tropical Diseases.

RESEARCH EXPERIENCE
Competitive grants participation:
November 2019 to present: Pre-doctoral Research Fellow at EU Patient-cEntric clinical tRial pLatform (EU-PEARL). Grant number 853966.
May 2019 to present: Pre-doctoral Research Fellow at European-Latin American TB Research Collaboration Network (EUSAT-RCS). Grant number: 823890.
Good clinical practice certificate: until April 23rd 2023.

PUBLICATIONS
First-author:
A restrospective study on the influence of sibling’s relatedness in Bolivian patients with
chronic Chagas disease. Parasites and Vectors. 2019 12:260
MDR Tuberculosis Treatment. Medicina (Kaunas). 2022 Jan 26;58(2):188. doi: 10.3390/medicina58020188.

Co-authored:
Ulcers on psoriatic plaques in a patient with advanced Human Immunodeficiency Virus infection. Enfermedades Infecciosas y Microbiología clínica, 2017 Nov;35(9):605-606. PMID 27240445.
Mixed connective tissue disease and epitope spreading: An Historical Cohort Study. Journal of Clinical Rheumatology. 2017 Apr;23(3): 155-159. PMID 28248800.
Usefulness of FDG PET/CT in the management of tuberculosis. PLoS ONE. 2019 14 (8): e0221516
Tigecycline-associated hypofibrinogenemia in a real-world setting. International Journal of Clinical Pharmacology. 2020 Aug;42(4):1184-1189. PMID: 32504166.
Blastocystis sp. carriage and irritable bowel syndrome: is the association already established? Biology. 2021, 10, 340.
Risk of SARS-COV-2 infection in previously infected and non-infected cohorts of health workers at high risk of exposure. Journal of Clinical Medicine. 2021 April, 10, 1968.
Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. Medicina Clinica. 2021 Jun 18:S0025-7753(21)00360-2. PMID: 34544604.
Impact of the COVID-19 pandemic on tuberculosis management in Spain. International Journal of Infectious Diseases. 2021 Jul;108:300-305. PMID: 33930543. Imported cystic echinococcosis in Spain: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2021 Oct 1;115(10):1184-1189. PMID: 33631003.

Other publications
Guía práctica de actuación en epidemias de COVID-19 en residencias para personas mayores. [Practical actuation guideline for COVID-19 epidemics in nursing facilities]. Sociedad Española de Medicina de Familia y Comunitaria. Enero 2021.